FNP-221

FNP-221 is a medical device currently in preclinical development by Alexza Pharmaceuticals and Ferrer for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). While specific details regarding the active pharmaceutical ingredient have not been publicly disclosed, the project is part of Alexza's pipeline, which centers on the proprietary Staccato inhalation technology. This platform is designed to deliver therapeutic agents as a thermally generated aerosol, allowing for rapid systemic or local absorption through the lungs, potentially offering a non-invasive alternative to intravenous therapies for severe respiratory and cardiovascular conditions.